On September 27, 2023, Azurity Pharmaceuticals, Inc. announced the closing of its acquisition of Slayback Pharma LLC from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity. Wilson Sonsini Goodrich & Rosati advised Azurity on IP matters related to the transaction.

The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.

The Wilson Sonsini team that advised Azurity on IP matters related to the acquisition includes Clark Lin, Wendy Devine, Ying Chen, Shu Boboila, Xiaoyang Tang, Kevin Tylock, and Johnson Truong.

For more information, please see Azurity’s press release.